Merck, Sinopharm sign statement of mutual intent for cooperation on HPV vaccine

Merck, known outside the U.S. and Canada as MSD, and Sinopharm (China National Pharmaceutical Group Corporation) today announced the signing of a statement of mutual intent. Under the statement, Sinopharm and Merck will cooperate on HPV vaccine and other mutually-selected vaccine products in China, and will also discuss the potential for promoting and marketing Merck's pharmaceutical products in China.

“We look forward to furthering our discussions with Sinopharm to establish a joint venture to significantly increase the number of people in China who have access to important vaccines.”

"Expanding our business in emerging markets throughout the world is critical to the mission and growth of Merck/MSD and innovative partnerships are a key element of our approach," said

Richard T. Clark, chairman and chief executive officer, Merck. "We look forward to furthering our discussions with Sinopharm to establish a joint venture to significantly increase the number of people in China who have access to important vaccines."

Merck and Sinopharm have maintained a good relationship for many years, Sinopharm said. Both Merck and Sinopharm expect the importance of public health will be elevated and the development of the pharmaceutical industry in China will be promoted through this strategic cooperation.